Twyman Research Management

Specialist consultants in
scientific project development,
management and presentation

Side-image

Welcome

to Twyman Research Management

Twyman Research Management Ltd is a UK company that specializes in scientific project development, management and presentation, including the preparation of research proposals, project management and reporting, project dissemination and complementary activities, and expert assistance with the preparation, editing and revision of scientific manuscripts.

We have been working for more than 20 years to develop and manage research projects and improve the quality of scientific publications.

Latest news

Launch of Horizon 2020 project InnCoCells

May 2021 - We are pleased to announce the launch of InnCoCells, a four-year Horizon 2020 project involving 17 partners from 11 European countries, with TRM Ltd representing the United Kingdom. The overall aim of the project is to revolutionize the way cosmetic ingredients are discovered and manufactured by developing sustainable production processes based on plants. TRM is leading work package 7, dealing with the project's dissemination and communication activities. The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 101000373.

For more information, see the project website here.

InCoCells project - image credit VTT
BLue-bg

Services Overview

We offer a range of services relating to the development, management and presentation of scientific projects

TRM-v3

Article of the Month

March 2022

Melt electrospinning is a manufacturing process in which fibres are formed from molten polymers. The liquid polymer is pushed through a nozzle into an electric field, which causes the formation of elongated jets. The cooling polymer fibres are then deposited onto a collector. The properties of the fibres depend on the temperature, take-up speed and various other parameters, and also on the presence of additives. In our article of the month for March, Siebert et al. tested two different additives as nucleation agents for their effect on fibre crystallinity and the corresponding mechanical properties. They found that the type and concentration of nucleating agents interacted with the spinning parameters to create a design space within which fibres of different mechanical characteristics could be produced. The simultaneous testing of different parameters will allow process improvements and optimization on a larger scale.

Article details: Siebert S et al. (2022) Nucleating agents to enhance poly(L-lactide) fiber crystallization during industrial-scale melt spinning. Polymers 14 (7) 1395.

Image shows melt-electrospun fibres.
Image credit: Daltster (CC BY-SA 3.0)

February 2022

Aureolysin is an enzyme and virulence factor secreted by the bacterium Staphylococcus aureus. More precisely, it is a metalloprotease, an enzyme that breaks down proteins and requires one or more metal ions as part of the catalytic mechanism. The biological role of aureolysin is to break down proteins from the host immune system, helping the bacterium to evade the immune response. Drugs that specifically inhibit aureolysin would therefore be ideal for the treatment of S. aureus infections. In February's article of the month, Mendes et al. engineered an insect metalloprotease inhibitor (IMPI) to increase its efficacy against aureolysin. They solved the crystal structure of aureolysin-IMPI complexes to determine the precise mechanism of action, allowing the design of IMPI mutants to bind and cleave aureolysin more efficiently. One of the mutants achieved a better inhibition constant than wild-type IMPI and is therefore suitable as a lead for the development of drugs against antibiotic resistant S. aureus strains,

Article details: Mendes SR et al. (2022) An engineered protein-based submicromolar competitive inhibitor of the Staphylococcus aureus virulence factor aureolysin. Comp Struct Biotechnol J 20, 534–544.

Image shows S. aureus cells.
Image credit: NIAID (CC BY-SA 2.0).

January 2022

Plants synthesize a diverse range of complex molecules known as secondary metabolites. These natural products can be exploited by humans as drugs, dyes, nutrients, flavors, perfumes and even poisons. In nature, secondary metabolites tend to be produced in very small quantities and many are toxic if they accumulate beyond a certain concentration. In January's article of the month, Buntru et al. show how cell-free expression systems based on plant cell lysates can overcome this barrier. Cell-free lysates are the internal contents of cells, but they are no longer alive and are therefore unaffected by toxins and inhibitors that kill plant cells or prevent them from growing and dividing. Lysates derived from tobacco cells were shown to produce four diverse metabolites when provided with the appropriate genetic constructs: lycopene (the red pigment from tomatoes, pictured), indigoidine (a blue pigment from bacteria) and two betalains (yellow/orange and red/violet pigments from plants such as beetroot). Cell lysates can now be developed to produce other metabolites, including valuable pharmaceutical structures.

Article details: Buntru M et al. (2022) Plant-derived cell-free biofactories for the production of secondary metabolites. Front Plant Sci 12, 794999.

Image shows powdered lycopene and some ripe tomatoes, a good natural source of lycopene.
Image credit: powdered lycopene by Jeff Dahl (CC BY-SA 3.0) and tomatoes by F Delventhal (CC BY 2.0).